Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice
Primary cutaneous follicle centre lymphoma Microchapters |
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice On the Web |
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
FDA on Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
CDC on Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice in the news |
Blogs on Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Soroush Seifirad, M.D.[3]
Overview
Diagnostic Study of Choice
Study of choice
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The following result of [gold standard test] is confirmatory of [disease name]:
- [Result 1]
- [Result 2]
OR
[Name of the investigation] must be performed when:
- The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
- A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
OR
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The diagnostic study of choice for [disease name] is [name of the investigation].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
OR
[Disease name] is primarily diagnosed based on the clinical presentation.
OR
Investigations:
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
The comparison of various diagnostic studies for [disease name]
Test | Sensitivity | Specificity |
---|---|---|
Test 1 | ...% | ...% |
Test 2 | ...% | ...% |
[Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity
Diagnostic results
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
- [Finding 1]
- [Finding 2]
Sequence of Diagnostic Studies
The [name of investigation] must be performed when:
- The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
- A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
- [Initial investigation]
- [2nd investigation]
Name of Diagnostic Criteria
It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
OR
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
- Criteria 1
- Criteria 2
- Criteria 3
OR
IF there are clear, established diagnostic criteria
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
IF there are no established diagnostic criteria
There are no established criteria for the diagnosis of [disease name].
Staging
Overview
Biopsy and pathologic studies are The staging of primary cutaneous follicle centre lymphoma is based on the International Society for Cutaneous Lymphomas (ISCL) / EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides / sezary syndrome.[1]
Staging
The staging of primary cutaneous follicle centre lymphoma is based on the International Society for Cutaneous Lymphomas (ISCL) / EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides / sezary syndrome.[1]
Name | Stage | Description |
---|---|---|
T | ||
T1 | Solitary skin involvement | |
T1a | A solitary lesion <5 cm diameter | |
T1 b | A solitary >5 cm diameter | |
T2 | Regional skin involvement: multiple lesions limited to 1 body region or 2 contiguous body regions | |
T2a | All-disease-encompassing in a <15-cm-diameter circular area | |
T2 b | All-disease-encompassing in a >15- and <30-cm-diameter circular area | |
T2 b | All-disease-encompassing in a >30-cm-diameter circular area | |
T3 | Generalized skin involvement | |
T3a | Multiple lesions involving 2 noncontiguous body regions | |
T3b | Multiple lesions involving ≥3 body regions | |
N | ||
N0 | No clinical or pathologic lymph node involvement | |
N1 | Involvement of 1 peripheral lymph node region that drains an area of current or prior skin involvement | |
N2 | Involvement of 2 or more peripheral lymph node regions or involvement of any lymph node region† that does not drain an area of current or prior skin involvement | |
N3 | Involvement of central lymph nodes | |
M | ||
M0 | No evidence of extracutaneous non–lymph node disease | |
M1 | Extracutaneous non–lymph node disease present |
International Society for Cutaneous Lymphomas (ISCL) / EORTC recommendations for staging evaluation in cutaneous lymphomas other than mycosis fungoides / sezary syndrome[1]
|
---|
Complete history/review of systems and physical examination |
Laboratory studies |
Complete blood count, comprehensive serum chemistries, serum LDH |
Whenever indicated, relevant flow cytometric studies of peripheral blood mononuclear cells |
Imaging studies |
CT of chest, abdomen and pelvis with contrast alone or with whole-body PET (18F-FDG); include CT or ultrasound of neck if clinically indicated |
Whole-body integrated PET/CT (as alternative imaging study to the standard contrast-enhanced CT) |
Bone marrow biopsy and aspirate |
Required in cutaneous lymphomas with intermediate to aggressive clinical behavior as categorized in the WHO-EORTC classification |
Should be considered in cutaneous lymphomas with indolent clinical behavior, but not required unless indicated by other staging assessments |
Additional studies as indicated clinically |
References
- ↑ 1.0 1.1 1.2 1.3 Kim, Y. H.; Willemze, R.; Pimpinelli, N.; Whittaker, S.; Olsen, E. A.; Ranki, A.; Dummer, R.; Hoppe, R. T. (2007). "TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)". Blood. 110 (2): 479–484. doi:10.1182/blood-2006-10-054601. ISSN 0006-4971.